The findings, published in Nature Communications, address one of the central problems in glioblastoma research: no two tumour cells are necessarily alike. Even within a single patient, cancer cells can differ in their growth patterns, biological behaviour and response to treatment. This cellular variation is one reason glioblastoma frequently returns after surgery, radiotherapy and chemotherapy. By examining the genetic activity of individual cells rather than treating a tumour as a uniform mass, the researchers were able to study its complexity at a far higher resolution.

The key focus of the investigation was isoforms, alternative versions of the molecular messages produced from the same gene. When a gene is activated, its DNA sequence is copied into RNA, which can then be processed in different ways. These alternative RNA molecules may produce proteins with distinct structures and functions. In cancer, changes in isoform production can influence how cells divide, invade surrounding tissue, resist treatment or interact with the immune system. Some isoforms may also create abnormal protein fragments that mark cancer cells for immune attack.

Until recently, scientists have struggled to investigate these molecules in individual tumour cells because standard single-cell sequencing technologies generally read only short fragments of RNA. Those fragments can reveal which genes are active, but they often cannot show the complete structure of a transcript. As a result, different isoforms may be difficult to distinguish, and rare tumour-specific versions can remain invisible. Long-read sequencing overcomes this limitation by reading much longer RNA molecules, allowing researchers to identify full-length transcripts and connect their molecular components accurately.

In this study, the team analysed data from more than 210,000 individual cells collected from 27 patients with glioblastoma. The analysis included malignant cells as well as immune cells and stromal cells in the tumour microenvironment—the network of non-cancerous cells and tissues that surrounds and supports a tumour. This broad approach enabled the researchers to examine not only the genetic diversity of the cancer itself, but also the molecular relationships between tumour cells and their local biological environment.

The resulting map contained thousands of previously unannotated isoforms, meaning genetic transcripts that had not been recorded in existing reference databases. Many of these newly identified isoforms appeared exclusively in tumour cells and were absent from healthy tissues examined in the analysis. Their restricted distribution is particularly important for drug development: a target found only in cancer cells could, in principle, be attacked without causing the widespread damage associated with targets shared by healthy organs.

The researchers then assessed whether some of the tumour-specific isoforms might generate neoantigens—abnormal protein fragments that can be displayed on the surface of cells by molecules known as major histocompatibility complex class I, or MHC class I. These molecules act like biological presentation platforms. They bind fragments derived from proteins inside a cell and display them to immune cells, including cytotoxic T cells. If the displayed fragment appears abnormal, T cells may recognise the cell as dangerous and destroy it.

A subset of the newly discovered isoforms was predicted to produce peptides capable of binding strongly to MHC class I molecules. This does not yet prove that the peptides trigger an effective immune response in patients, but it identifies candidates for further laboratory and clinical testing. If validated, such molecules could expand the supply of neoantigens available for personalised cancer vaccines, in which a vaccine is designed around the unique molecular features of an individual patient’s tumour. They could also support the development of engineered T-cell therapies or other precision immunotherapy strategies.

The implications are significant, but the discovery is not an immediate change to glioblastoma treatment. The predicted neoantigens must first be confirmed experimentally, including tests showing that they are naturally produced by tumour cells, presented on MHC molecules and recognised by human immune cells. Researchers will also need to determine how consistently these isoforms occur among patients and whether cancer cells can lose them under immune pressure. Nevertheless, the study provides a new route into a previously inaccessible layer of tumour biology, potentially revealing targets missed by gene-level and short-read analyses.

The project also demonstrates the value of combining clinical expertise, brain tumour surgery, oncology and population-scale genomics. By linking long-read sequencing with single-cell analysis, the team established and validated an analytical framework that could be applied to other cancers and clinical datasets. The researchers say the work strengthens Hong Kong’s role in translational genomics and precision medicine. For glioblastoma, a disease that has resisted many conventional therapeutic approaches, the newly exposed world of tumour-specific isoforms may offer one of the most promising sources of future targets for personalised vaccines and immune-based treatments.

Subject of Research: Glioblastoma and tumour-specific isoform diversity

Article Title: Mapping glioblastoma’s isoform diversity using long-read single-cell analysis

News Publication Date: 23 April 2026

Web References: https://www.nature.com/articles/s41467-026-72258-2

References: Nature Communications, DOI: 10.1038/s41467-026-72258-2

Image Credits: The University of Hong Kong

Keywords: glioblastoma, brain cancer, long-read sequencing, single-cell analysis, isoforms, neoantigens, personalised cancer vaccines, immunotherapy, precision medicine, tumour microenvironment

The therapeutic landscape surrounding STING agonists has long been characterized by a paradox: potent preclinical efficacy often fails to translate into consistent clinical success. The heterogeneity in tumor responsiveness has perplexed oncologists and researchers alike, prompting a rigorous examination of intra-tumoral molecular circuits that might elucidate these disparities. Predominantly, prior focus gravitated toward STING’s modulation of the tumor immune microenvironment, sometimes neglecting the autonomous tumor-cell-intrinsic pathways that potentially dictate sensitivity or resistance to these agonists.

A collaborative team of scientists spanning several prestigious Chinese institutions—including the First Medical Center of the Chinese PLA General Hospital and Peking University School of Life Sciences—sought to decode this enigma at a molecular resolution. Their seminal study, published in the renowned journal Cancer Biology & Medicine in late 2025, meticulously delineates how STING activation precipitates a STAT1-dependent transcriptional cascade culminating in the upregulation of HMGN2, which in turn orchestrates tumor cell apoptosis. These findings spotlight the critical role of tumor-intrinsic signaling cascades in mediating therapeutic outcomes and offer a mechanistic framework for leveraging STING agonists with newfound precision.

Experimental interrogation began with a comprehensive survey of diverse tumor cell lines to gauge their susceptibility to STING agonist treatment. Strikingly, neural-origin tumors—specifically neuroblastoma and glioblastoma—exhibited robust proliferative inhibition upon exposure to the synthetic STING agonist SR-717. Contrastingly, several non-neural carcinomas demonstrated scant response, underscoring the tissue-specific nature of this effect. Furthermore, murine xenograft models recapitulated these results, even under immunodeficient conditions, suggesting that the antitumor activity transcends conventional immune cell engagement and hinges upon intrinsic tumor cell pathways.

To unravel the molecular architecture underlying this phenomenon, the researchers deployed high-throughput RNA sequencing, which unveiled a constellation of differentially expressed genes post-STING activation. Central among these was HMGN2, a nucleosome-binding protein previously implicated in chromatin remodeling but now unveiled as a linchpin in apoptotic execution. Functional assays confirmed that overexpressing HMGN2 in tumor cells independently triggered apoptosis, whereas CRISPR-mediated HMGN2 knockout abrogated the antitumor efficacy of STING agonists, decisively establishing causality.

The axis linking STING activation and HMGN2 transcription was further explored through mechanistic studies revealing the indispensable role of STAT1, a well-characterized transcription factor commonly downstream of interferon signaling. Chromatin immunoprecipitation assays elegantly demonstrated STAT1’s direct binding to promoter regions of HMGN2, forming a previously uncharacterized STING–STAT1–HMGN2 signaling axis. This pathway operates as an autonomous molecular conduit within tumor cells, effecting apoptotic programs that culminate in tumor suppression independent of canonical immune responses.

Beyond mechanistic insights, bioinformatic analyses leveraging publicly accessible oncologic datasets reinforced the clinical relevance of HMGN2. Elevated HMGN2 transcript levels correlated positively with improved patient survival across various malignancies, positioning this protein not only as a therapeutic mediator but also as a valuable prognostic biomarker. This dual role opens the tantalizing prospect of employing HMGN2 expression as a stratification tool to identify patients most apt to benefit from STING-targeted interventions.

The implications of this research resonate deeply within the field of precision oncology. Historically, the application of STING agonists has been hamstrung by unpredictable patient responses and an absence of reliable biomarkers. By shifting the paradigm to acknowledge tumor cell-intrinsic regulation as a determinant of efficacy, clinicians may soon tailor treatments guided by molecular profiling of the STING–STAT1–HMGN2 axis. Such stratification promises to optimize therapeutic indices, maximize patient benefit, and reduce unwarranted exposure to ineffective regimens.

The neuro-oncology domain stands to gain substantially from these findings. Given the aggressive nature and immunosuppressive microenvironment characteristic of nervous system tumors such as glioblastoma, therapeutic strategies that circumvent immune evasion mechanisms are critically needed. STING agonists capable of directly engaging tumor-intrinsic apoptotic pathways may represent a paradigm shift, offering a novel modality to target these recalcitrant malignancies with enhanced specificity and potency.

Looking forward, this discovery invites exploration into combination therapies designed to potentiate HMGN2 expression or restore the sensitivity of resistant tumors to STING modulation. Agents that synergize with STAT1 activation or chromatin remodeling may amplify apoptotic cascades, thereby broadening the therapeutic window. Additionally, the universality of the STING–STAT1–HMGN2 axis suggests potential applicability beyond neural tumors, warranting investigation across diverse cancer types where STING pathway engagement remains underexploited.

This transformative insight into the molecular determinants governing tumor responses to STING agonists underscores the evolution of cancer immunotherapy from a primarily immune-centric strategy to an integrated approach encompassing direct tumor cell targeting. It exemplifies how dissecting intracellular signaling networks can reveal critical vulnerabilities previously masked by the complexity of tumor-immune interactions. Ultimately, these advances herald a future wherein STING agonists transcend their experimental roots to become tailored, mechanism-driven weapons in the oncologist’s arsenal.

As the clinical community wrestles with the formidable challenge of durable, effective cancer treatments, the STING–STAT1–HMGN2 axis emerges as a beacon illuminating new therapeutic and diagnostic horizons. By harnessing the intrinsic apoptotic machinery within tumor cells, this pathway offers a compelling template for the next generation of immunotherapeutic innovations. The journey from bench to bedside is poised to leverage these findings, translating molecular discovery into tangible clinical impact with the promise of improved patient outcomes.

Subject of Research: Not applicable

Article Title: Antitumor effects of STING agonists on nervous system tumors via tumor-intrinsic STING-STAT1-mediated HMGN2 expression

News Publication Date: 30-Oct-2025

References:
DOI: 10.20892/j.issn.2095-3941.2025.0326

Image Credits: Cancer Biology & Medicine

Keywords: Agonists, STING pathway, STAT1, HMGN2, tumor-intrinsic signaling, nervous system tumors, neuroblastoma, glioblastoma, apoptosis, immunotherapy, cancer biomarkers, precision oncology